There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA – Research Report), IDEAYA Biosciences (IDYA – Research Report) and Pharming Group (PHGUF – Research Report) with bullish sentiments.
Neumora Therapeutics, Inc. (NMRA)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Neumora Therapeutics, Inc. on May 7 and set a price target of $29.00. The company’s shares closed last Friday at $9.19, close to its 52-week low of $8.82.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
Neumora Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $29.00.
See today’s best-performing stocks on TipRanks >>
IDEAYA Biosciences (IDYA)
RBC Capital analyst Gregory Renza maintained a Buy rating on IDEAYA Biosciences on May 7 and set a price target of $53.00. The company’s shares closed last Friday at $41.17.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
Currently, the analyst consensus on IDEAYA Biosciences is a Strong Buy with an average price target of $53.56, which is a 31.8% upside from current levels. In a report issued on May 7, Citi also maintained a Buy rating on the stock with a $60.00 price target.
Pharming Group (PHGUF)
In a report released yesterday, Alistair Campbell from RBC Capital maintained a Buy rating on Pharming Group, with a price target of EUR1.65. The company’s shares closed last Friday at $0.95, close to its 52-week low of $0.91.
According to TipRanks.com, Campbell is ranked #2298 out of 8834 analysts.
Currently, the analyst consensus on Pharming Group is a Moderate Buy with an average price target of $1.99, representing a 108.6% upside. In a report issued on May 8, Stifel Nicolaus also maintained a Buy rating on the stock with a EUR2.05 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NMRA:
- Neumora Therapeutics reports Q1 EPS (34c), consensus (34c)
- Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Neumora Therapeutics falls 23% after FDA clinical hold of Phase 1 NMRA-266 study
- Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
- Neumora Therapeutics announces clinical hold of Phase 1 NMRA-266 study
